Part 2/Chapter 4/15-min read

Aortic Aneurysmal Disease

AAA epidemiology, screening, surveillance, and open vs endovascular repair strategies

Background

Aneurysmal disease spans abdominal (4Aneurysms), thoracic (6Thoracic Aortic), thoracoabdominal (6Thoracic Aortic), and peripheral arterial beds and remains a leading cause of sudden vascular death due to rupture. AAA prevalence in men ≥65 years is approximately 1.5–4.5% and lower in women, who have higher rupture risk at smaller diameters . Thoracic aneurysms are less common but carry high lethality, particularly in connective tissue disorders (Marfan, Loeys–Dietz, vascular Ehlers–Danlos). Peripheral aneurysms (popliteal, femoral, visceral, renal) often coexist with AAA . Population screening of older men reduces AAA-related mortality and emergent repairs, and contemporary guidelines define who to screen and how to surveil detected AAAs . For peripheral arterial disease management, see 10PAD.

Etiology

Aneurysm development results from the interplay of genetic predisposition, hemodynamic stress, and degenerative changes in the arterial wall . The most common etiology is atherosclerosis, which leads to intimal injury, medial degeneration, and loss of elastic fibers. Genetic factors play a significant role, with hereditary connective tissue disorders (Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome) causing abnormalities in extracellular matrix proteins . Additional etiologies include infection (mycotic aneurysms), inflammatory conditions (Takayasu arteritis, giant cell arteritis), trauma, and iatrogenic injury. Management of infected aneurysms is discussed in the complications section, and genetic thresholds for repair are detailed in 6the thoracic aneurysm chapter.

Pathophysiology

  1. Proteolysis of extracellular matrix → loss of elastin and collagen .
  2. Inflammatory infiltration (macrophages, CD4+ T cells) → cytokine release, oxidative stress .
  3. Biomechanical stress → wall shear stress, Laplace law: ↑ diameter → ↑ wall tension → progressive dilation .
  4. Genetics and epigenetics → TGF-β signaling pathways in 6Thoracic Aortic/6Thoracic Aortic .
  5. Intraluminal thrombus (ILT) acts as a bioreactor sustaining hypoxia, protease activity, and mural neovascularization, contributing to wall weakening in 4Aneurysms .
  6. Distinct biology in 6Thoracic Aortic/6Thoracic Aortic (medial degeneration, smooth muscle apoptosis, TGF-β signaling abnormalities) vs atherosclerotic 4Aneurysms; clinical implications include different thresholds in genetic aortopathy .

Diagnostics

Measurement standards should be applied consistently to improve reproducibility. For abdominal aortic aneurysm (AAA), measure the outer-to-outer diameter in the anteroposterior plane at the point of maximal dilation. For endovascular aneurysm repair (EVAR) planning, centerline-of-flow measurements are essential for accurate device sizing . These standardized approaches reduce interobserver variability and ensure comparable surveillance data across imaging studies .

Complex Anatomy Challenges

  • Hostile neck features: short (<10–15 mm), severe angulation (>60°), conical shape, heavy thrombus/calcification—associated with higher Type Ia endoleak/migration .
  • Thoracoabdominal aortic aneurysm (TAAA): classify extent (Crawford I–V); enumerate visceral involvement; plan for spinal cord protection and access.
  • Hostile iliofemoral anatomy: severe calcification, tortuosity, or small vessel diameter may necessitate the use of open iliac conduits (OIC) to enable the delivery of large-bore endovascular devices, providing a safe and effective adjunct for patients with challenging access .
  • Implications include the balance of off-instructions for use (IFU) endovascular aneurysm repair (EVAR) risk against fenestrated endovascular aneurysm repair (FEVAR), branched endovascular aneurysm repair (BEVAR), or open repair .

Abdominal Aortic Aneurysm

Screening and surveillance of intact abdominal aortic aneurysm (AAA): Population-based screening programs target men aged 65–75 years with a history of smoking, as this group demonstrates the highest prevalence and cost-effectiveness for one-time ultrasound screening. Selective screening may be considered for men ≥65 years without smoking history and for women ≥65 years with smoking history or family history of AAA. First-degree relatives of AAA patients should be offered a one-time ultrasound screening at age ≥65 years. Once detected, small AAAs require systematic surveillance: aneurysms measuring 3.0–3.9 cm should be monitored annually, those measuring 4.0–4.9 cm every 6 months, and those measuring 5.0–5.4 cm every 3 months or proceed directly to repair planning if appropriate .

Key Trials and Registries

Landmark RCTs (endovascular aneurysm repair (EVAR)-1/2, DREAM, OVER, ACE) showed lower 30-day mortality with EVAR vs open repair , with no long-term survival advantage and higher late reinterventions for EVAR. Fifteen-year EVAR trial follow-up and OVER trial long-term results inform counseling and surveillance. Complex repairs (FEVAR/BEVAR/PMEG/ChEVAR) lack RCTs; multicenter registries demonstrate high technical success and acceptable early/medium-term outcomes in experienced centers .

General Principles

  • Ruptured abdominal aortic aneurysm (rAAA), ruptured thoracic aortic aneurysm (rTAA), and ruptured iliac aneurysms are life-threatening emergencies with overall mortality often >50% including prehospital deaths .
  • Regionalized pathways with 24/7 computed tomography angiography (CTA), endovascular capability, blood products, and hybrid operating rooms (ORs) are recommended .
  • Initial management includes permissive hypotension (target systolic blood pressure 70–90 mmHg), massive transfusion protocol (MTP), and rapid CT-based triage in stable or semi-stable patients . In patients with profound shock, resuscitative endovascular balloon occlusion of the aorta (REBOA) may be utilized as a bridge to definitive repair. An endovascular aneurysm repair (EVAR)-first strategy is feasible in many rAAA and supported by randomized strategy data.

Ruptured Abdominal Aortic Aneurysm

  • Epidemiology & outcomes: rAAA carries near-universal mortality without repair; contemporary 30-day mortality after repair is ~30–40% across series .
  • Guidelines: An endovascular aneurysm repair (EVAR)-first approach is recommended when anatomically feasible and resources are available ; open repair remains essential for unsuitable anatomy or lack of endovascular capability .
  • Evidence: Randomized strategy trials (e.g., IMPROVE) found similar 30-day mortality between EVAR-first and open strategies overall , validating CT-based triage and showing benefits in process measures (faster discharge home, cost) and in EVAR-capable centers . Absolute mortality reductions should be interpreted with caution in the absence of center-specific data.
  • Technical considerations: Prioritize local/regional anesthesia, percutaneous access, and rapid proximal seal for rEVAR; for open repair, expeditious clamp placement and hemorrhage control. Post-repair: aggressive hemodynamic optimization, renal protection, abdominal compartment syndrome (ACS) surveillance, and early imaging when feasible.

Related: For comprehensive management of ACS following rAAA repair, see 17Ch. 17.

Ruptured Iliac Artery Aneurysms

  • Ruptured iliac artery aneurysms (IAA) are uncommon; many coexist with abdominal aortic aneurysm (AAA) and are treated within an aorto-iliac repair strategy. Postoperative outcomes are significantly worse for patients undergoing repair of ruptured versus unruptured IAA .
  • Endovascular aneurysm repair (EVAR) is preferred when anatomy allows, with hypogastric preservation via iliac branch devices if feasible; internal iliac embolization may be necessary but increases risk of buttock claudication and pelvic ischemia .
  • Open repair remains important when endovascular seal or access is not possible or in the presence of infection. Current guidelines recommend a threshold of ≥3.5 cm for elective repair of isolated common iliac artery aneurysms (CIAA) .

Peripheral Aneurysms

  • Popliteal aneurysm: Consider elective repair for asymptomatic PAAs ≥25 mm (2.5 cm) ; earlier repair at 20–24 mm if substantial mural thrombus, documented distal embolization, or poor runoff. Symptomatic PAAs (thromboembolism, compression) warrant repair regardless of size. Prefer open bypass with autogenous vein in good-risk patients; endovascular stent-grafts for select high-risk/anatomy . For detailed management, see 5Chapter 5 .
  • Common femoral aneurysm: Consider repair at ≥3.5 cm or when thrombus is present or symptomatic; favor open repair .
  • Visceral artery aneurysms: Splenic, hepatic, renal, SMA—repair when ≥2.0–3.0 cm (artery-specific), symptomatic, enlarging, or in women of child-bearing potential; endovascular therapy (coil/plug/covered stent) is increasingly first-line in suitable anatomy .

Complications

Endoleaks are classified into five types based on their source and mechanism . Type I (proximal or distal attachment site) and Type III (fabric tear or component separation) endoleaks represent device failure with ongoing pressurization of the aneurysm sac and require urgent reintervention. Type II endoleaks (from branch vessels such as lumbar or inferior mesenteric arteries) are common (15–25% of cases) and typically managed with observation unless associated with sac growth >5 mm, in which case selective embolization may be indicated. Type IV (graft porosity) endoleaks usually resolve spontaneously. Type V endoleaks, or endotension, describe persistent sac expansion without identifiable leak on imaging and may warrant conversion to open repair.

Migration and limb occlusion occur when inadequate fixation or progressive neck dilation allows device movement or when limb stenosis/kinking develops. Risk factors include short necks, severe angulation, large initial neck diameter, and lack of proximal fixation (suprarenal vs infrarenal devices). Management includes extension cuffs, relining with aortic extenders, or limb thrombectomy with adjunctive femorofemoral bypass when endovascular salvage is not feasible.

Branch vessel occlusion after fenestrated or branched endovascular aneurysm repair (EVAR) represents a serious complication requiring prompt recognition and intervention. Renal or mesenteric artery occlusion may present with acute kidney injury, flank pain, or abdominal symptoms. Salvage techniques include catheter-directed thrombolysis, mechanical thrombectomy, angioplasty with stenting, or open revascularization depending on the timing and extent of occlusion.

Spinal cord ischemia (SCI) remains the most feared complication of thoracoabdominal aortic repair, with incidence ranging from 3–15% depending on extent of coverage . Prevention strategies include preoperative risk stratification, selective cerebrospinal fluid (CSF) drainage (maintain CSF pressure <10 mmHg), maintenance of mean arterial pressure >80–90 mmHg, correction of anemia (hemoglobin >10 g/dL), and revascularization of the left subclavian artery and hypogastric arteries when appropriate . Treatment involves immediate optimization of spinal cord perfusion through the same principles. For detailed 6Thoracic Aortic management, see 6Chapter 6.

Colonic ischemia after aortoiliac repair results from interruption of mesenteric collateral flow, particularly when inferior mesenteric and hypogastric arteries are sacrificed simultaneously. Recognition requires high clinical suspicion with symptoms of left-sided abdominal pain, bloody diarrhea, or peritoneal signs. Early colonoscopy aids diagnosis; management ranges from supportive care for mucosal ischemia to emergent laparotomy and resection for transmural infarction.

Access complications include arterial dissection, occlusion, bleeding, and pseudoaneurysm formation. Prevention strategies include careful pre-procedural imaging, appropriate sheath sizing, ultrasound-guided access, and consideration of conduit placement in hostile groins. Acute kidney injury (AKI) occurs in 10–30% of complex aortic procedures due to contrast nephropathy, atheroembolism, or renal ischemia. Prevention includes optimization of hydration status, minimization of contrast volume, use of iso-osmolar contrast agents, and selective renal artery protection during complex repairs.

Follow-up

Antithrombotic therapy after endovascular aortic repair typically consists of single antiplatelet therapy (aspirin 81–325 mg daily) unless another indication exists for dual antiplatelet therapy or anticoagulation. Contrast-sparing strategies should be employed in patients with renal dysfunction, including use of duplex ultrasound as the primary surveillance modality when feasible , judicious use of contrast-enhanced ultrasound, and reservation of computed tomography angiography (CTA) for specific clinical indications such as suspected complications or sac growth .

Screening and surveillance of intact small AAA (pre-repair)

Screening target populations include men aged 65–75 years with a history of ever-smoking, with selective screening for men ≥65 without smoking history and women with smoking or family history. Screening is also recommended for first-degree relatives. Surveillance intervals are determined by maximal diameter: 3.0–3.9 cm annually; 4.0–4.9 cm every 6 months; and 5.0–5.4 cm every 3 months or expedited workup for repair. Ultrasound is the primary modality. Trial data demonstrate that screening reduces abdominal aortic aneurysm (AAA)-related mortality , consistent with SVS 2018 schedules .

AAA Surveillance Intervals by Diameter

Decision threshold

3.0–3.9 cm

Which value triggers which action?

3.0–3.9 cm
Every 12 months
Continue surveillance
4.0–4.9 cm
Every 6 months
Continue surveillance
5.0–5.4 cm
Every 3 months
Consider repair workup
≥5.5 cm (men) / ≥5.0 cm (women)
Recommend elective repair
Rapid growth (≥0.5 cm/6 mo)
Recommend repair

Explicit repair thresholds and sex-specific considerations

Elective repair of asymptomatic 4Aneurysms is generally recommended at ≥5.5 cm in men and should be considered at ≥5.0 cm in women, given the higher rupture risk at smaller diameters. Repair is also indicated for rapid growth (≥0.5 cm in 6 months or ≥1.0 cm/year) or symptoms. Shared decision-making is emphasized for elderly or frail patients .

AAA Repair Thresholds

TreatmentMen (asymptomatic)
Men (asymptomatic)
**Repair Threshold**
≥5.5 cm
**Evidence**
SVS 2018, ESVS 2024
Women (asymptomatic)
**Repair Threshold**
≥5.0 cm
**Evidence**
SVS 2018 (higher rupture risk)
Rapid growth
**Repair Threshold**
≥0.5 cm/6 mo or ≥1.0 cm/yr
**Evidence**
SVS 2018
Symptomatic
**Repair Threshold**
Any size
**Evidence**
Immediate evaluation

Evidence synthesis of EVAR vs open for intact AAA with long-term outcomes

Endovascular aneurysm repair (EVAR) reduces 30-day mortality vs open repair, but long-term overall survival is similar with higher late aneurysm-related deaths and reinterventions in EVAR; This is supported by long-term EVAR trials and the OVER trial ; the DREAM trial confirms early benefit with convergence over time .

IMPROVE trial and rAAA management

IMPROVE randomized strategy trial showed similar 30-day mortality between endovascular aneurysm repair (EVAR)-first and open strategies, confirmed safety of CT-based triage, and suggested improved outcomes in EVAR-capable centers; 3-year data show no overall mortality difference but faster discharge home and cost advantages in EVAR-capable centers .

UK Small Aneurysm Trial (UKSAT) and ADAM context for small AAA

The UKSAT and ADAM trials demonstrated no survival advantage with early elective surgery for 4.0–5.4 cm AAAs, supporting surveillance until the threshold size is reached .

Definitions and nomenclature (infrarenal, juxtarenal, pararenal, suprarenal) and hostile neck criteria

Definitions distinguish juxtarenal (no normal neck but no involvement of renal arteries), pararenal (involves at least one renal artery), and suprarenal (extends above renal arteries) aneurysms. Hostile neck criteria include short length (<10–15 mm), >60° angulation, conical neck, and thrombus or calcification. These features have significant implications for the choice between off-IFU endovascular aneurysm repair (EVAR) and FEVAR/ChEVAR .

Iliac artery aneurysm thresholds and iliac branch device strategy

Repair of common iliac artery aneurysms should be considered at ≥3.5 cm, or earlier if rapid growth or symptoms occur, while internal iliac aneurysms are typically repaired at ≥3.0 cm. Hypogastric preservation with iliac branch devices is preferred when feasible; otherwise, internal iliac embolization may be necessary, observing for buttock claudication and colonic ischemia risks .

Medical optimization and pharmacotherapy

Medical optimization includes smoking cessation (strongly recommended), statin therapy for atherosclerotic risk reduction, blood-pressure control, and antiplatelet therapy for cardiovascular indications. No pharmacotherapy has definitively slowed abdominal aortic aneurysm (AAA) growth ; thus, the routine use of doxycycline, beta-blockers, or ACE inhibitors solely for this indication is not recommended .

Post-repair antithrombotic and imaging surveillance strategy tailoring

Single antiplatelet therapy (aspirin) is recommended after endovascular aneurysm repair (EVAR)/FEVAR/BEVAR unless another indication exists for DAPT or anticoagulation. Duplex-first surveillance should be adopted in low-risk EVAR patients with a stable or shrinking sac and no endoleak at 1 year. Computed tomography angiography (CTA) is reserved for concerning findings, complex repairs, or sac growth .

Clinical Reference Tables

Table 4.1Risk FactorsMajor Risk Factors for Aneurysm Formation
Non-modifiable
**Risk Factors**
Age, Male sex, Family history, Genetic disorders (Marfan, Loeys-Dietz, Ehlers-Danlos)
Modifiable
**Risk Factors**
Smoking, Hypertension, Hyperlipidemia, Atherosclerosis, Inflammation
Other factors
**Risk Factors**
Chronic obstructive pulmonary disease (COPD), Aortic wall infection, Trauma/Iatrogenic injury
Table 4.2Comparison of abdominal aortic aneurysm (AAA) Repair Options
Comparison A

Open repair

Strengths
  • Durable
  • long-term survival
Trade-offs
  • Higher perioperative risk
  • longer recovery
Comparison B

Standard endovascular aneurysm repair (EVAR)

Strengths
  • Minimally invasive
  • lower early mortality
Trade-offs
  • Requires suitable anatomy
  • reinterventions
Comparison C

FEVAR/BEVAR

Strengths
  • Allows treatment of complex anatomy
Trade-offs
  • Custom-made
  • technical complexity
Comparison D

PMEG

Strengths
  • On-table modification for urgent cases
Trade-offs
  • Off-label
  • operator-dependent
Comparison E

Chimney/ChEVAR

Strengths
  • Off-the-shelf
  • useful in emergencies
Trade-offs
  • Higher risk of endoleak (Type Ia
  • gutter)
Table 4.3ClassificationEndoleak Classification
I
**Description**
Proximal or distal seal failure
**Clinical significance**
High rupture risk → reintervention
II
**Description**
Retrograde filling via branch (IMA, lumbar)
**Clinical significance**
Most common, usually benign
III
**Description**
Graft defect or modular disconnection
**Clinical significance**
High rupture risk → urgent repair
IV
**Description**
Graft porosity
**Clinical significance**
Rare with modern grafts
V
**Description**
Endotension (no visible leak, sac expansion)
**Clinical significance**
Unclear, may require surveillance
Table 4.4SurveillanceSurveillance Protocols After Aneurysm Repair
  • EVAR
    **1 mo**
    computed tomography angiography (CTA)/DUS
    **12 mo**
    CTA/DUS
    **Annual**
    CTA/DUS
    **Guideline Source**ESVS 2024, SVS 2018
  • FEVAR/BEVAR
    **1 mo**
    CTA
    **6 mo**
    CTA
    **12 mo**
    CTA
    **Annual**
    Annual CTA
    **Guideline Source**Vascunet, ESVS 2024
  • thoracic endovascular aortic repair (TEVAR)
    **1 mo**
    CTA
    **6 mo**
    CTA
    **12 mo**
    CTA
    **Annual**
    Annual CTA
    **Guideline Source**SVS 2018
  • Open AAA
    **Annual**
    Symptom-driven
    **Guideline Source**SVS 2018
  • Popliteal aneurysm repair
    **1 mo**
    DUS
    **12 mo**
    DUS
    **Annual**
    Annual DUS
    **Guideline Source**ESVS 2024

References

  1. 1.
    Dawson I, et al. Popliteal artery aneurysms: epidemiology and association with AAA. *Br J Surg*. 1997. PubMed
    PubMed-indexed article1997
  2. 2.
    Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926.
    PubMed-indexed article2014
  3. 3.
    ESVS. Review of the European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms: what is new and prospects for development. 2024. PMID: 41801947. DOI: 10.33029/1027-6661-2024-30-2-131-136.
    PubMed-indexed articleClinical practice guideline2024
  4. 4.
    Ashton HA, et al. The Multicentre Aneurysm Screening Study (MASS): a randomized controlled trial of ultrasonographic screening for abdominal aortic aneurysms. Lancet. 2002;360(9345):1531-1539.
    PubMed-indexed article2002

    The results provide reliable evidence of benefit from screening for abdominal aortic aneurysms, and the Multicentre Aneurysm Screening Study was designed to assess whether or not such screening is beneficial.

  5. 5.
    Chaikof EL, et al. SVS Guidelines on AAA management and surveillance. *J Vasc Surg*. 2018;67:2–77. PubMed. Follow-up recommendations.
    PubMed-indexed article2018

    A door‐to‐intervention time of <90 minutes is suggested, based on a framework of 30‐30‐30 minutes, for the management of the patient with a ruptured aneurysm, and the Vascular Quality Initiative mortality risk score is suggested for mutual decision‐making with patients considering aneurYSm repair.

  6. 6.
    Sakalihasan N, Michel JB, et al. Abdominal aortic aneurysms. *Nat Rev Cardiol*. 2018;15:225–37. PubMed. AAA biology.
    PubMed-indexed article2018

    Elective repair of AAA with open surgery or endovascular aortic repair (EVAR) should be considered to prevent AAA rupture, although the morbidity and mortality associated with both techniques remain non-negligible.

  7. 7.
    Sun Z. CT angiography of AAA. *Biomed Imaging Interv J*. 2011;7:e2. PubMed. CTA review.
    PubMed-indexed article2011

    Patients can benefit from multislice CT angiography that provides a rapid and accurate diagnosis while avoiding unnecessary invasive coronary Angiography procedures, with a focus on the diagnostic accuracy of coronary artery disease.

  8. 8.
    Litinas K et al. Open Iliac Conduits Enabling the New Era of Endovascular Aortic Repair in Hostile Iliofemoral Anatomy: A Single-Center Retrospective Study. Medicina. 2025. PMID: 41597304.
    PubMed-indexed articleRegistry / cohort2025
  9. 9.
    Oderich GS, et al. BEVAR outcomes. *J Vasc Surg*. 2017. PubMed
    PubMed-indexed article2017

    AWT predicts solid organ infarction, renal function deterioration, and longer time to resume enteral diet after F‐BEVAR of pararenal and type IV TAAAs and presents a new classification system for assessment of AWT burden.

  10. 10.
    Oikonomou K, et al. ChEVAR outcomes (PERICLES). *J Vasc Surg*. 2019. PubMed
    PubMed-indexed article2019

    A model where integrin &agr;v and cellular interactions with the extracellular matrix are required to maintain VANGL2 protein levels and thus function at the plasma membrane is supported.

  11. 11.
    Becquemin JP, et al. ACE trial. *J Vasc Surg*. 2011. PubMed
    PubMed-indexed article2011

    In patients with low to intermediate risk factors, open repair of AAA is as safe as EVAR and remains a more durable option.

  12. 12.
    Blankensteijn JD, et al. DREAM. *NEJM*. 2005. PubMed
    PubMed-indexed article2005
  13. 13.
    Greenhalgh RM, et al. EVAR-1: endovascular vs open AAA repair. *NEJM*. 2010;362:1863–71. PubMed. Landmark EVAR trial.
    PubMed-indexed article2010

    In this large, randomized trial, endovascular repair of abdominal aortic aneurysm was associated with a significantly lower operative mortality than open surgical repair and was associated with increased rates of graft-related complications and reinterventions and was more costly.

  14. 14.
    Katsargyris A, et al. PMEG for complex AAA. *J Vasc Surg*. 2017. PubMed
    PubMed-indexed article2017

    Surgical outcomes and survival for patients evaluated by preoperative DUS imaging alone for PAE are equivalent to patients evaluated with CA or CTA, and PSVs in the tibiopopliteal arteries may predict the need for fasciotomy.

  15. 15.
    Lederle FA, Freischlag JA, Kyriakides TC, et al.; OVER Veterans Affairs Cooperative Study Group. Long-Term Comparison of Endovascular and Open Repair of Abdominal Aortic Aneurysm. N Engl J Med. 2012;367:1988–1997.
    PubMed-indexed article2012

    Endovascular repair led to increased long-term survival among younger patients but not among older patients, for whom a greater benefit from the endovascular approach had been expected, but rupture after repair remained a concern.

  16. 16.
    Lederle FA, et al. OVER trial. *NEJM*. 2012. PubMed
    PubMed-indexed article2012

    Endovascular repair is a cost-effective alternative to open repair in the US VA healthcare system for at least the first two years and is both more effective and less costly for life-years and QALYs.

  17. 17.
    Powell JT, et al. Final 15-year follow-up of the UK endovascular aneurysm repair trials (EVAR-1 and EVAR-2). Lancet. 2016;388(10058):2366-2374.
    PubMed-indexed article2016

    EVAR has an early survival benefit but an inferior late survival compared with open repair, which needs to be addressed by lifelong surveillance of EVAR and re-intervention if necessary.

  18. 18.
    European Society for Vascular Surgery (ESVS). 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases. Eur J Vasc Endovasc Surg. 2025. PMID: 41448425. DOI: 10.1016/j.ejvs.2025.12.050.
    PubMed-indexed articleClinical practice guideline2025

    These 2025 ESVS clinical practice guidelines provide comprehensive and up to date advice to physicians and patients on the management of diseases of the mesenteric and renal arteries and veins.

  19. 19.
    Powell JT, et al. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 3-year follow-up of the IMPROVE randomized trial. BMJ. 2017;359:j4859.
    PubMed-indexed article2017

    The genome of a new STLV-1 subtype b from a 43-year-old male gorilla with T-cell lymphoma is reported, indicating a new lineages of primate T- cell lymphocytic viruses.

  20. 20.
    Powell JT, Sweeting MJ, Ulug P, et al.; IMPROVE Trial Investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30-day outcomes. N Engl J Med. 2014;371:112–121.
    PubMed-indexed article2014

    There is no evidence regarding the effects of increased supervision on educational value or future quality of care, as with duty-hour restrictions, with an attendant perceived loss of autonomy in decision making.

  21. 21.
    Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022. PMID: 36322642.
    PubMed-indexed articleClinical practice guideline2022
  22. 22.
    Laloo R, et al. Postoperative outcomes are significantly worse among patients undergoing repair of ruptured versus unruptured iliac artery aneurysms – a 10-year longitudinal cohort study. BJS. 2022. DOI: 10.1093/bjs/znac242.066.
    DOI publisher routeRegistry / cohort2022
  23. 23.
    Cassar K, et al. Randomized trial of endovascular vs open repair for popliteal aneurysm. *Ann Surg*. 2005;241:502–8. PubMed. Popliteal aneurysm evidence.
    PubMed-indexed article2005

    Carotid ePTFE interposition graft replacement seems to be safe and durable and to have no increased perioperative risk or altered intermediate-term outcomes.

  24. 24.
    ESVS Guidelines on the Management of Aneurysmal Disease. *Eur J Vasc Endovasc Surg*. 2020. PubMed
    PubMed-indexed article2020

    Novel carbohydrate mimics were designed which contain two 5a-carba-d-glucose residues, one each at reducing and nonreducing end, and thus these mimics are 5a,5a'-dicarba- d- glucobioses.

  25. 25.
    Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed. 2022. Ch. 71, Arterial Aneurysms: Etiology, Epidemiology, and Natural History, p. 1143
    Textbook
    Textbook referenceTextbook2022

    Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed.. 2022. Ch. 71, Arterial Aneurysms: Etiology, Epidemiology, and Natural History, p. 1143

    Textbook reference
  26. 26.
    Aburahma AF, Campbell JE, Mousa AY, et al. Clinical Practice Guidelines for Follow-up of Patients after Endovascular Aneurysm Repair. J Vasc Surg. 2019;70(1):335–342.
    PubMed-indexed article2019

    It is reasonable to consider the implementation of ERAS pathways in the care of vascular surgery patients, specifically those undergoing open aortic operations, but many of the details will be based on limited data and extrapolation from other surgical specialties until further research is done.

  27. 27.
    UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance of small abdominal aortic aneurysms. Lancet. 1998;352(9141):1649-1655.
    PubMed-indexed article1998

    Findings indicate that low-dose OCs can be maintained in young women with FNH, and the largest FNH disappeared 2 years after the first diagnosis, whereas the other FNH remained unchanged.

  28. 28.
    Golledge J, et al. Medical therapies to limit AAA growth. *Lancet Diabetes Endocrinol*. 2017;5:185–93. PubMed. AAA medical management.
    PubMed-indexed article2017

    Continuous efforts to develop a medical therapy to limit abdominal aortic aneurysm growth are described, with no benefit reported of the antibiotic doxycycline, a mast cell inhibitor, an angiotensin‐converting enzyme inhibitor, or a calcium channel blocker in limiting AAA growth.

  29. 29.
    Meijer CA, Stijnen T, Wasser MN, et al. Doxycycline for Abdominal Aortic Aneurysm Growth: A Randomized Trial. N Engl J Med. 2018;379:341–351.
    PubMed-indexed article2018
  30. 30.
    ESVS. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024. PMID: 38307694. DOI: 10.1016/j.ejvs.2023.11.002.
    PubMed-indexed articleClinical practice guideline2024
  31. 31.
    Swedvasc Annual Report 2022. National vascular registry, Sweden. Link. Registry outcomes.
    No stable evidence link
    ucr.uu.se2022
  32. 32.
    Vascunet 2021 Report. Complex aortic interventions across Europe.
    PubMed-indexed article2021

    The emergence of carbapenem-non-susceptible AmpC/ESBL co-occurring Enterobacterales and colistin non-sUSceptible carbAPenemases co- Occurring K. pneumoniae highlights potential therapeutic challenges in the Asia-Pacific region.

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.